[A20-84] Darolutamide (prostate cancer) - Addendum to Commission A20-43
Last updated 15.10.2020
Commission awarded on 08.09.2020 by the Federal Joint Committee (G-BA).
|Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease|
|Conclusion of dossier assessment A20-43 unchanged|
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.